West Pharmaceutical Services (NYSE:WST) Now Covered by Analysts at Rothschild & Co Redburn

Key Points

• Analysts at Rothschild & Co Redburn have initiated coverage on West Pharmaceutical Services (NYSE:WST), assigning a "buy" rating with a price target of $311.00, indicating a potential upside of 22.68% from its previous close.
• The company's recent earnings report revealed an EPS of $1.84, surpassing estimates and showing a 9.2% revenue increase year-over-year.
• West Pharmaceutical Services has a consensus rating of "Moderate Buy" from analysts, with an average price target of $319.50.

Investment analysts at Rothschild & Co Redburn started coverage on shares of West Pharmaceutical Services (NYSE:WST - Get Free Report) in a research report issued on Monday. The brokerage set a "buy" rating and a $311.00 price target on the medical instruments supplier's stock. Rothschild & Co Redburn's price objective would suggest a potential upside of 22.68% from the company's previous close.

A number of other research firms have also recently commented on WST. Wall Street Zen raised West Pharmaceutical Services from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Evercore ISI increased their price objective on West Pharmaceutical Services from $275.00 to $350.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Citigroup reaffirmed a "buy" rating on shares of West Pharmaceutical Services in a research report on Thursday, May 22nd. UBS Group raised their target price on West Pharmaceutical Services from $285.00 to $320.00 and gave the company a "buy" rating in a research report on Friday, July 25th. Finally, Barclays assumed coverage on West Pharmaceutical Services in a research report on Tuesday, June 24th. They set an "equal weight" rating and a $245.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $319.50.

West Pharmaceutical Services Trading Down 3.9%

Shares of WST stock opened at $253.50 on Monday. The business has a 50-day moving average of $241.04 and a 200 day moving average of $225.44. The stock has a market capitalization of $18.23 billion, a PE ratio of 37.95, a P/E/G ratio of 4.50 and a beta of 1.05. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.78 and a quick ratio of 2.08. West Pharmaceutical Services has a 1-year low of $187.43 and a 1-year high of $352.33.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its earnings results on Thursday, July 24th. The medical instruments supplier reported $1.84 EPS for the quarter, beating analysts' consensus estimates of $1.51 by $0.33. West Pharmaceutical Services had a return on equity of 18.43% and a net margin of 16.48%.The company had revenue of $766.50 million during the quarter, compared to analysts' expectations of $725.11 million. During the same quarter last year, the business posted $1.52 EPS. The firm's revenue for the quarter was up 9.2% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2025 guidance at 6.650-6.850 EPS. As a group, sell-side analysts anticipate that West Pharmaceutical Services will post 6.62 earnings per share for the current year.

Hedge Funds Weigh In On West Pharmaceutical Services

Large investors have recently bought and sold shares of the business. Zions Bancorporation National Association UT acquired a new position in West Pharmaceutical Services in the first quarter valued at $25,000. CYBER HORNET ETFs LLC purchased a new position in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $25,000. Quarry LP purchased a new position in shares of West Pharmaceutical Services during the 1st quarter worth approximately $27,000. Vermillion & White Wealth Management Group LLC boosted its position in West Pharmaceutical Services by 193.9% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 144 shares of the medical instruments supplier's stock worth $32,000 after acquiring an additional 95 shares during the last quarter. Finally, First Horizon Advisors Inc. boosted its position in West Pharmaceutical Services by 85.0% during the first quarter. First Horizon Advisors Inc. now owns 185 shares of the medical instruments supplier's stock worth $41,000 after acquiring an additional 85 shares during the last quarter. Hedge funds and other institutional investors own 93.90% of the company's stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.